Clevudine launched for hepatitis B in the Philippines
This article was originally published in Scrip
Executive Summary
Eisai's in-licensed antiviral Revovir (clevudine) has been approved for hepatitis B in the Philippines, the second country to grant the product regulatory clearance after South Korea.